Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Arrhythmias and Conduction Disorders in Hsct Publisher



Haghjoo M1 ; Fazelifar AF1 ; Ashrafi F2 ; Zaboli E3 ; Enamzadeh E1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cardiac Electrophysiology Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Hematology Oncology, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Hematology and Oncology, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Source: Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation Published:2024


Abstract

Cardiac complications, particularly arrhythmias and conduction disorders, present significant challenges in the management of patients undergoing hematopoietic stem-cell transplantation Hematopoietic Stem Cell Transplantation (HSCT) (HSCT). Despite the relatively low incidence of these complications, which is reported to be less than 10%, their impact on non-relapse mortality and quality of life is substantial. This study aimed to review the types, risk factors, mechanisms, diagnosis, and management of various arrhythmias seen in HSCT recipients. Supraventricular arrhythmias like atrial fibrillation and atrial flutter are the most common arrhythmias observed, occurring in 7-27% of patients. Chemotherapy Chemotherapy drugs used for HSCT conditioning like anthracyclines, alkylating agents, and proteasome inhibitors have been shown to cause arrhythmias through various mechanisms. Factors like older age, pre-existing cardiovascular disease, mediastinal irradiation, graft-versus-host disease increase arrhythmia risk. Detailed evaluation including electrocardiography, ambulatory monitoring aids diagnosis. Management depends on arrhythmia type and involves rate or rhythm control, anticoagulation, drug dose reduction/change based on complications. Close collaboration between cardiologists and oncologists is needed for regular monitoring, prevention, and timely treatment of arrhythmias in HSCT patients given their impact on outcomes. © Springer Nature Switzerland AG 2024. All rights reserved.